Gallbladder Cancer - Pipeline Review, H2 2017 - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "Gallbladder Cancer - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Gallbladder Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 14, 4 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

1. Introduction
2. Gallbladder Cancer - Overview
3. Gallbladder Cancer - Therapeutics Development
4. Pipeline Overview
5. Pipeline by Companies
6. Pipeline by Universities/Institutes
7. Products under Development by Companies
8. Products under Development by Universities/Institutes
9. Gallbladder Cancer - Therapeutics Assessment
10. Assessment by Target
11. Assessment by Mechanism of Action
12. Assessment by Route of Administration
13. Assessment by Molecule Type
14. Gallbladder Cancer - Companies Involved in Therapeutics Development
    

• 4SC AG
• Advenchen Laboratories LLC
• Array BioPharma Inc
• Aslan Pharmaceuticals Pte Ltd
• Bayer AG
• BeiGene Ltd
• Eli Lilly and Co
• Halozyme Therapeutics Inc
• Hutchison MediPharma Ltd
• Ipsen SA
• Kringle Pharma Inc
• Leap Therapeutics Inc
• MedImmune LLC
• Molecular Templates Inc
• Novartis AG
• NuCana Plc
• OncoTherapy Science Inc
• VasGene Therapeutics Inc

For more information about this report visit https://www.researchandmarkets.com/research/dhzpfg/gallbladder?w=4